Ligand Pharmaceuticals LGND Non-cash Income From Financial Royalty Assets
Non-cash Income From Financial Royalty Assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:NonCashIncomeFromFinancialRoyaltyAssets.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's non-cash income from financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's non-cash income from financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported non-cash income from financial royalty assets of -$4.8M in Q1 2026.
- How has Ligand Pharmaceuticals's non-cash income from financial royalty assets changed year-over-year?
- Ligand Pharmaceuticals's non-cash income from financial royalty assets decreased by 1140.3% year-over-year, from $461K to -$4.8M.
- What is the long-term trend for Ligand Pharmaceuticals's non-cash income from financial royalty assets?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's non-cash income from financial royalty assets has grown at a 274.6% compound annual growth rate (CAGR), from $164K to $8.62M.
- What does non-cash income from financial royalty assets mean?
- This metric reflects the non-cash revenue or income recognized from financial royalty assets, often related to the effective interest method or valuation adjustments of royalty streams. It distinguishes accounting-based income recognition from actual cash royalty receipts. Understanding this helps investors assess the quality of earnings derived from the company's intellectual property portfolio.